Investigational drug · Phase 3
SHR-2004
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prevention of Arterial and Venous Thrombosis, Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "SHR-2004"
First trial start
2024
Feb 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-2004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prevention of Arterial and Venous Thrombosis
- Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Approved drugs for the same conditions: Ovarian cancer · Oncology · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-2004" as an intervention, largest first.
- A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyPivotal-lookingCompleted
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06825416 · 1,165 participants · Start Mar 16, 2025 · Primary completion Feb 15, 2026
Drug: SHR-2004 injection; SHR-2004 injection and 4 more · For: Prevention of Arterial and Venous Thrombosis
Sites: Beijing, China; Changsha, China
- SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyPivotal-lookingCompleted
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT05752461 · 353 participants · Start Apr 12, 2023 · Primary completion Apr 12, 2024
Drug: SHR-2004 injection; SHR-2004 injection and 2 more · For: Prevention of Venous Thromboembolism After Knee Arthroplasty
Sites: Changsha, China
- A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer SurgeryPivotal-lookingCompleted
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06220123 · 225 participants · Start Feb 16, 2024 · Primary completion Dec 31, 2024
Drug: SHR-2004; Enoxaparin Sodium Injection; Rivaroxaban Tablets · For: Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Sites: Hangzhou, China
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy SubjectsStatus unknown
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT05369767 · 64 participants · Start May 24, 2022 · Primary completion Jan 30, 2023
Drug: SAD, SHR-2004; SAD, SHR-2004 placebo · For: Prevention of Arterial and Venous Thrombosis
Sites: Nanjing, China
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06280768 · 10 participants · Start Apr 10, 2024 · Primary completion Jan 10, 2025
Drug: SHR-2004 injection · For: Atrial Fibrillation
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.
Jiang G, Tang J, Zhao H, et al. · Am J Hematol 2026
- Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study.
Jiang J, Wang Y, Zhang Y, et al. · Clin Pharmacokinet 2026
- The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects.
Ma T, Weng Z, Cao B, et al. · Expert Opin Investig Drugs 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.